Specialty Pharmacy

Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.

Bill Sullivan, executive director of SPAARx, describes how his organization's definition of "specialty pharmacy" compares with other entities' definitions.

Debbie Stern of Rxperts discusses the findings from the EMD Serono Specialty Digest, 9th Edition, and the use of specialty drug tiers by payers.

Roche today announced that the FDA has accepted the company's Biologics License Application (BLA) for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia (CLL).